Aridis Pharmaceuticals, Inc., announced today the appointment of former Gilead Sciences executive Craig Gibbs, Ph.D., MBA, to its Board of Directors. Dr. Gibbs’ broad expertise spans nearly three decades in a variety of research and business roles, including contributing to the development and commercial...
Aridis Pharmaceuticals, Inc., announced today the initiation of a Phase 1 clinical study of Aerucin™, the Company’s broadly reactive, fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia....
Aridis Pharmaceuticals, Inc., announced today the appointment of Paul-Andre de Lame, M.D., as the Company’s Chief Medical Officer....
Aridis Pharmaceuticals, Inc., announced today that the Company is scheduled to present at the Biotech Showcase™ 2015 taking place in San Francisco, CA on January 12-14, 2015....
Aridis Pharmaceuticals, Inc., announced today the addition of Stephen Opal, M.D., an internationally recognized key opinion leader in the areas of pneumonia and sepsis to the Company’s scientific advisory board....
Aridis Pharmaceuticals, Inc., announced today the closing of private placements totaling $6.75 million....